3,582 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,582 shares of the medical equipment provider's stock, valued at approximately $350,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LNTH. Jones Financial Companies Lllp lifted its holdings in shares of Lantheus by 108.3% during the fourth quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider's stock worth $203,000 after purchasing an additional 1,182 shares during the period. Victory Capital Management Inc. raised its position in Lantheus by 13.4% during the fourth quarter. Victory Capital Management Inc. now owns 87,130 shares of the medical equipment provider's stock valued at $7,795,000 after acquiring an additional 10,297 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Lantheus during the fourth quarter valued at approximately $36,183,000. Amundi raised its position in Lantheus by 529.5% during the fourth quarter. Amundi now owns 176,952 shares of the medical equipment provider's stock valued at $16,633,000 after acquiring an additional 148,842 shares in the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in Lantheus during the fourth quarter valued at approximately $136,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 3.0%

Lantheus stock opened at $81.31 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The business has a 50 day simple moving average of $80.26 and a 200-day simple moving average of $89.94. The stock has a market capitalization of $5.63 billion, a PE ratio of 23.10 and a beta of 0.12. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business's revenue was up .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.69 earnings per share. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Truist Financial reduced their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, B. Riley reduced their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $131.20.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.